BioAge Labs (BIOA) investor relations material

Platform and data strategy

• Platform leverages 50 million molecular data points from decades of human aging, enabling identification of early molecular changes that precede disease and predict longevity.

• Recent integration of HUNT Biobank data from Norway adds 17,000 samples with over 30 years of health records, enriching the platform for cardiometabolic and neurodegenerative disease targets.

• Discovery platform is unique for its long-term follow-up and ability to identify novel targets before disease onset, differentiating it from other biobanks.

• Ongoing and potential pharma collaborations validate the platform and provide funding, with partnerships focused on novel target discovery and molecule development.

• AI and machine learning are integrated into target discovery, molecule identification, and operational processes, enhancing efficiency and innovation.

Lead programs and clinical development

• Lead asset BGE-102 is a brain-penetrant NLRP3 inhibitor targeting obesity, with best-in-class potential for potency and brain penetration.

• Phase 1 study for BGE-102 began in August, with a once-daily oral dosing paradigm; initial SAD results expected by year-end, including pharmacodynamic markers and safety data.

• Preclinical data show BGE-102 induces weight loss comparable to semaglutide and demonstrates additive effects when combined with incretin therapies.

• Long-term vision includes fixed-dose oral combinations with GLP-1 agonists, aiming for both monotherapy and combination therapy in obesity.

• Phase 1 package will enable rapid expansion into other indications such as osteoarthritis and Parkinson’s, based on emerging data.

Pipeline and future catalysts

• APJ agonist programs (biologic and small molecule) target muscle retention and synergistic weight loss when combined with appetite suppressants; both are on track for IND filings by end of next year.

• Previous clinical experience with APJ agonists supports the mechanism for muscle preservation, with next-generation compounds designed to avoid prior safety issues.

• Oral and injectable APJ agonist options are being developed, with a focus on combination therapies for weight loss and maintenance.

• Additional early-stage programs are advancing in partnership with Eli Lilly and others, focusing on metabolic aging targets.

• Key upcoming milestones include BGE-102 SAD data by year-end, MAD data in 2026, monotherapy obesity trial readout by end of next year, and IND filings for APJ programs by end of 2026.